-
Something wrong with this record ?
Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents
J. Vančo, J. Gáliková, J. Hošek, Z. Dvořák, L. Paráková, Z. Trávníček,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Anti-Inflammatory Agents chemistry pharmacology therapeutic use MeSH
- Edema drug therapy MeSH
- Hepatocytes drug effects MeSH
- Hypoxanthines chemistry pharmacology therapeutic use MeSH
- Rats MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Cell Line, Tumor MeSH
- Neoplasms drug therapy MeSH
- Antineoplastic Agents chemistry pharmacology therapeutic use MeSH
- Spectroscopy, Fourier Transform Infrared MeSH
- Inflammation drug therapy MeSH
- Gold chemistry pharmacology therapeutic use MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15022955
- 003
- CZ-PrNML
- 005
- 20150709122653.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0109901 $2 doi
- 035 __
- $a (PubMed)25333949
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vančo, Ján $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 245 10
- $a Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents / $c J. Vančo, J. Gáliková, J. Hošek, Z. Dvořák, L. Paráková, Z. Trávníček,
- 520 9_
- $a The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x chemie $x farmakologie $x terapeutické užití $7 D000893
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a edém $x farmakoterapie $7 D004487
- 650 _2
- $a zlato $x chemie $x farmakologie $x terapeutické užití $7 D006046
- 650 _2
- $a hepatocyty $x účinky léků $7 D022781
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoxanthiny $x chemie $x farmakologie $x terapeutické užití $7 D007042
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $7 D017550
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gáliková, Jana $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Hošek, Jan $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Dvořák, Zdeněk $u Regional Centre of Advanced Technologies and Materials & Department of Cell Biology and Genetics, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Paráková, Lenka $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Trávníček, Zdeněk $u Regional Centre of Advanced Technologies and Materials & Department of Inorganic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 10 (2014), s. e109901
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25333949 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150709122712 $b ABA008
- 999 __
- $a ok $b bmc $g 1083294 $s 905948
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 10 $d e109901 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20150709